Skip to main content

Advertisement

SpringerLink
Log in

Italian consensus statement on paediatric HIV infection

  • Consensus Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

The objective of this document is to identify and reinforce current recommendations concerning the management of HIV infection in infants and children in the context of good resource availability. All recommendations were graded according to the strength and quality of the evidence and were voted on by the 57 participants attending the first Italian Consensus on Paediatric HIV, held in Siracusa in 2008. Paediatricians and HIV/AIDS care specialists were requested to agree on different statements summarizing key issues in the management of paediatric HIV. The comprehensive approach on preventing mother-to-child transmission (PMTCT) has clearly reduced the number of children acquiring the infection in Italy. Although further reduction of MTCT should be attempted, efforts to personalize intervention to specific cases are now required in order to optimise the treatment and care of HIV-infected children. The prompt initiation of treatment and careful selection of first-line regimen, taking into consideration potency and tolerance, remain central. In addition, opportunistic infection prevention, adherence to treatment, and long-term psychosocial consequences are becoming increasingly relevant in the era of effective antiretroviral combination therapies (ART). The increasing proportion of infected children achieving adulthood highlights the need for multidisciplinary strategies to facilitate transition to adult care and maintain strategies specific to perinatally acquired HIV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. The Italian Register for HIV Infection in Children. Update report April 2009.

  2. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522–8.

    Article  CAS  PubMed  Google Scholar 

  3. Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, et al. Incidence of opportunistic and other infections in HIV-infected children in the ART era. JAMA. 2006;296:292–300.

    Article  CAS  PubMed  Google Scholar 

  4. Selik RM, Lindegren ML. Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999. Pediatr Infect Dis J. 2003;22:635–41.

    Article  PubMed  Google Scholar 

  5. Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, et al. National Study of HIV in Pregnancy and Childhood Collaborative HIV Paediatric Study. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019.

    Article  CAS  PubMed  Google Scholar 

  6. McConnell MS, Byers RH, Frederick T, Peters VB, Dominguez KL, Sukalac T, et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989–2001. J Acquir Immune Defic Syndr. 2005;38:488–94.

    Article  PubMed  Google Scholar 

  7. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996–2006: planning for teenage and adult care. Clin Infect Dis. 2007;45:918–24.

    Article  PubMed  Google Scholar 

  8. Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, et al. Key questions in antiretroviral therapy: Italian consensus workshop (2005). J Antimicrob Chemother. 2006;57:1055–64.

    Article  CAS  PubMed  Google Scholar 

  9. The European Mode of Delivery Collaboration. Elective caesarian-section vs. vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999;353:1035–39.

    Google Scholar 

  10. The International Perinatal HIV Group. Mode of delivery and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. N Engl J Med. 1999;340:977–87.

    Article  Google Scholar 

  11. Kind C, Rudin C, Siegrist CA, Wyler CA, Biedermann K, Lauper U, et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS. 1998;12:205–10.

    Article  CAS  PubMed  Google Scholar 

  12. Thorne C, Newell ML. HIV. Semin Fetal Neonatal Med. 2007;12:174–81.

    Article  PubMed  Google Scholar 

  13. European HIV in Obstetrics Group. Higher rates of post-partum complications in HIV infected than in uninfected women irrespective of mode of delivery. AIDS. 2004;18:933–8.

    Article  Google Scholar 

  14. Read JS, Newell ML. Cesarean delivery for prevention of mother-to-child transmission of HIV. Cochrane Database Syst Rev 2005;4. doi:10.1002/14651858.CD005479.

  15. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458–65.

    Article  Google Scholar 

  16. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1- infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–94.

    CAS  PubMed  Google Scholar 

  17. Galli L, Puliti D, Chiappini E, Gabbiano C, Ferrarsi G, Mignone F, Vigano A, Giaquinto C, Genovese O, Anzi dei G, Badolato R Buffolato W, Maccabruni A, Salvini F, Cellini M, Ruggeri M, Manzionna M, Bernardi S, Tovo P, De Martino M on behalf of Italian Register for HIV infection in children. Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1? Clin Infect Dis 2009;48:1310–17.

    Google Scholar 

  18. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA. 2000;283:1167–74.

    Article  CAS  PubMed  Google Scholar 

  19. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–80.

    Article  CAS  PubMed  Google Scholar 

  20. The Italian Register for HIV Infection in Children. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch Pediatr Adolesc Med. 2002;156:915–21.

    Google Scholar 

  21. Mandelbrot L, Le Chenadec J, Berrebi A, Bongain A, Bénifla JL, Delfraissy JF, et al. Perinatal HIV-1 transmission—interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA. 1998;280:55–60.

    Article  CAS  PubMed  Google Scholar 

  22. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, et al. International PACTG 316 Team. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. A randomized trial. JAMA. 2002;288:189–98.

    Article  CAS  PubMed  Google Scholar 

  23. Van Rompay KK, Greenier JL, Marthas ML, Otsyula MG, Tarara RP, Miller CJ, et al. Immediate zidovudine treatment protects simian immunodeficiency virus- infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother. 1995;39:125–31.

    PubMed  Google Scholar 

  24. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine [lett]. Science. 1995;270:1197–9.

    Article  CAS  PubMed  Google Scholar 

  25. Böttiger D, Johansson NG, Samuelsson B, Zhang H, Putkonen P, Vrang L, et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS. 1997;11:157–62.

    Article  PubMed  Google Scholar 

  26. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409–14.

    Article  CAS  PubMed  Google Scholar 

  27. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Bénifla JL, Burgard M, et al. Lamivudine–zidovudine combination for prevention on maternal–infant transmission of HIV-1. JAMA. 2001;285:2083–93.

    Article  CAS  PubMed  Google Scholar 

  28. Guay GE, Urban M, Chersich MF, Bolton C, van Niekerk R, Violari A, Stevens W, McIntyre JA; for the PEP Study Group. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child transmission on infants of untreated mothers. AIDS 2005;19:1289–97.

    Google Scholar 

  29. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med. 2000;343:982–91.

    Article  CAS  PubMed  Google Scholar 

  30. European AIDS Clinical Society. Guidelines—clinical management and treatment of HIV-infected adults in Europe 2009. http://www.europeanaidsclinicalsociety.org.

  31. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med. 1996;335:1621–9.

    Article  CAS  PubMed  Google Scholar 

  32. Read JS, American Academy of Pediatrics, Committee on Pediatric AIDS. Human milk, breastfeeding, and transmission of human immunodeficiency virus type 1 in the United States. Pediatrics. 2003;112:1196–205.

    Article  PubMed  Google Scholar 

  33. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR. 2006;55:1–17.

    Google Scholar 

  34. Havens PL, Mofenson LM, American Academy of Pediatrics, Committee on Pediatric AIDS. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics. 2008;122:1127–34.

    Article  Google Scholar 

  35. Fiscus SA, Schoenbach VJ, Wilfert C. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med. 1999;340:1040–1.

    Article  CAS  PubMed  Google Scholar 

  36. Read JS, Committee on Pediatric AIDS, American Academy of Pediatrics. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics. 2007;120:1547–62.

    Article  Google Scholar 

  37. European Collaborative Study. Increased risk of adverse pregnancy outcomes in ART-treated HIV-infected women in Europe. AIDS. 2004;17:2337–9.

    Google Scholar 

  38. Public Health Service Task Force. Safety and toxicity of individual antiretroviral agents in pregnancy. Supplement to PHSTF Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. PHSTF, 2004. http://aidsinfo.nih.gov.

  39. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS. 2003;17:2053–61.

    Article  CAS  PubMed  Google Scholar 

  40. European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1 infected mothers. AIDS. 2004;18:2009–17.

    Article  Google Scholar 

  41. Townsend C, Schulte J, Thorne CL, Dominguez K, Cortina Borja M, Packham CS, Bohannon B, Tookey P. Exploring heterogeneity in the association between HAART and prematurity in three observational studies. 13th Observational workshop on Observational databases, Lisbon 26–28 March 2009.

  42. Noguera A, Fortuny C, Muñoz-Almagro C, Sanchez E, Vilaseca MA, Artuch R, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics. 2004;114:598–604.

    Article  Google Scholar 

  43. Ekouevi DK, Touré R, Becquet R, Viho I, Sakarovitch C, Rouet F, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: agence Nationale de Recherches Sur le SIDA et les Hepatites Virales 1209 study, Abidjan, Ivory Coast. Pediatrics. 2006;118:1071–7.

    Article  Google Scholar 

  44. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084–9.

    Article  CAS  PubMed  Google Scholar 

  45. Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J. 2003;22:782–9.

    Article  PubMed  Google Scholar 

  46. Giaquinto C, De Romeo A, Giacomet V, Rampon O, Ruga E, Burlina A, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS. 2001;15:1074–5.

    Article  CAS  PubMed  Google Scholar 

  47. Dominguez K, Bertolli J, Fowler M, Peters V, Ortiz I, Melville S, et al. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA. Ann N Y Acad Sci. 2000;918:236–46.

    Article  CAS  PubMed  Google Scholar 

  48. The European Collaborative Study. Hospitalization of children born to human immunodeficiency virus infected women in Europe. Pediatr Infect Dis J. 1997;16:1151–6.

    Article  Google Scholar 

  49. Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis. 2008;197:398–404.

    Article  PubMed  Google Scholar 

  50. Walker AS, Doerholt K, Sharland M, Gibb DM, Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004;18:1915–24.

    Article  PubMed  Google Scholar 

  51. Gibb D, Giaquinto C. Children with HIV infection: special cases. Lancet. 2000;356:s34.

    Article  PubMed  Google Scholar 

  52. Ometto L, De Forni D, Patiri F, Trouplin V, Mammano F, Giacomet V, et al. Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. AIDS. 2002;16:839–49.

    Article  PubMed  Google Scholar 

  53. The European Collaborative Study. Age-related standards for T lymphocytes subsets based on uninfected children born to HIV-infected women. Pediatr Infect Dis J. 1992;11:1018–26.

    Article  Google Scholar 

  54. Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L, et al. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J Infect Dis. 2005;192:296–302.

    Article  PubMed  Google Scholar 

  55. De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis. 2002;186:312–20.

    Article  PubMed  Google Scholar 

  56. Bagnarelli P, Vecchi M, Burighel N, Bellanova D, Menzo S, Clementi M, et al. Genotypic and phenotypic correlates of the HIV type 1 env gene evolution in infected children with discordant response to antiretroviral therapy. AIDS Res Hum Retrovir. 2004;20:1306–13.

    Article  CAS  PubMed  Google Scholar 

  57. Patel K, PENTA group 219 study team, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis. 2008;46:1751–60.

    Article  CAS  PubMed  Google Scholar 

  58. Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Gattinara GC, et al. Changing patterns of clinical events inperinatally HIV-1 infected children during the era of HAART. AIDS. 2007;21:1607–15.

    Article  PubMed  Google Scholar 

  59. World Health Organisation: Antiretroviral therapy for HIV infection in infants and children: Towards universal access Recommendations for a public health approach http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf.

  60. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. February 23, 2009; pp 1–139. http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf.

  61. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM, on behalf of the PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004;5:61–86.

    Article  PubMed  Google Scholar 

  62. Zanchetta M, Anselmi A, Vendrame D, Rampon O, Giaquinto C, Mazza A, et al. HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Therapy. 2008;13:47–55.

    CAS  Google Scholar 

  63. Palma P, Romiti ML, Cancrini C, Pensieroso S, Montesano C, Bernardi S, et al. Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants. Vaccine. 2008;26:5196–201.

    Article  CAS  PubMed  Google Scholar 

  64. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.

    Article  CAS  PubMed  Google Scholar 

  65. Fraaij PL, Rakhmanina N, Burger D, de Groot R. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit. 2004;26:122–6.

    Article  PubMed  Google Scholar 

  66. HIV Paediatric Prognostic Markers Collaborative Study Group. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS. 2006;20:1289–94.

    Article  Google Scholar 

  67. Newell ML, Patel D, Goetghebuer T, Thorne C, European Collaborative Study. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis. 2006;193:954–62.

    Article  CAS  PubMed  Google Scholar 

  68. Faye A, Le Chenadec J, Dollfus C, Thuret I, Douard D, Firtion G, et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis. 2004;39:1692–8.

    Article  PubMed  Google Scholar 

  69. Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, Guarino A, et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS. 2006;20:207–15.

    Article  CAS  PubMed  Google Scholar 

  70. Van der Linden D, Hainaut M, Goetghebuer T, Haelterman E, Schmitz V, Maes P, et al. Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Pediatr Infect Dis J. 2007;26:359–61.

    Article  PubMed  Google Scholar 

  71. Aboulker JP, Babiker A, Chaix ML, Compagnucci A, Darbyshire J, Debre M, Faye A, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004;18:237–245.

    Google Scholar 

  72. Goetghebuer T, Haelterman E, Le Chenadec J, Dolfus C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS. 2009;23:597–604.

    Article  PubMed  Google Scholar 

  73. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233–44.

    Article  CAS  PubMed  Google Scholar 

  74. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355: 2283–96.

    Google Scholar 

  75. Emery S, SMART Study Group and INSIGHT. Major clinical outcomes in patients not treated with antiretroviral therapy at baseline in SMART: a rationale for a trial to examine early treatment of HIV disease [Abstract WEPEB018]. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia, 2007.

  76. Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, et al. Rate of AIDS diseases or death in HIV infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS. 2007;21:1717–2721.

    Article  PubMed  Google Scholar 

  77. Green H, Gibb DM, Walker AS, Pillay D, Butler K, Candeias F, et al. Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007;21:947–55.

    Article  CAS  PubMed  Google Scholar 

  78. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39:1038–46.

    Article  CAS  PubMed  Google Scholar 

  79. Wensing AM, van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958–66.

    Article  PubMed  Google Scholar 

  80. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005;332:179–80.

    Google Scholar 

  81. Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40:468–74.

    Article  CAS  PubMed  Google Scholar 

  82. Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N, Wilson CM; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Prevalence of primary HIV drug resistance among recently infected adolescents: a multicenter Adolescent Trials Network study: ATN 029. 13th Conference on Retroviruses and Opportunistic Infections; February 5–8, 2006; Denver, CO. Abstract # 21.

  83. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.

    CAS  PubMed  Google Scholar 

  84. Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109:61.

    Article  Google Scholar 

  85. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999;18:682–9.

    Article  CAS  PubMed  Google Scholar 

  86. Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004;190:271–9.

    Article  CAS  PubMed  Google Scholar 

  87. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16:2175–82.

    Article  CAS  PubMed  Google Scholar 

  88. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR, et al. Adolescent Medicine HIV/AIDS Research Network. Barriers to ART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157:249–55.

    Article  PubMed  Google Scholar 

  89. Gibb DM on behalf of the PENTA 11 team. Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA 11 trial). J Int AIDS Soc. 2008;11, abs 021.

    Google Scholar 

  90. Ryan M, Griffin S, Chitah B, Walker AS, Mulenga V, Kalolo D, et al. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS. 2008;22:749–57.

    Article  PubMed  Google Scholar 

  91. WHO (2006) Guidelines on co-trimoxazole prophylaxis for HIV related infections among children, adolescents, and adults in resource-limited settings. http://www.who.int/hiv/pub/guidelines/ctx/en/index.html.

  92. Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics. 2005;115:488–94.

    Article  Google Scholar 

  93. Esposito S, Bojanin J, Porta A, Cesati L, Gualtieri L, Principi N. Discontinuation of secondary prophylaxis for Pneumocystis Pneumonia in human immunodeficiency virus–infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J. 2005;24:1117–20.

    Article  PubMed  Google Scholar 

  94. Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med. 1999;340:1301–6.

    Article  CAS  PubMed  Google Scholar 

  95. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med. 2001;344:168–74.

    Article  CAS  PubMed  Google Scholar 

  96. Dankner WM, Lindsey JC, Levin MJ, Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J. 2001;20:40–8.

    Article  CAS  PubMed  Google Scholar 

  97. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991;325:73–80.

    Google Scholar 

  98. Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med. 1994;331:1181–7.

    Article  CAS  PubMed  Google Scholar 

  99. Moss WJ, Clements CJ, Halsey NA. Immunization of children, at risk of infection with human immunodeficiency virus. Bull World Health Organ. 2003;81:61–70.

    PubMed  Google Scholar 

  100. Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine. 2003;21:S35–7.

    Article  PubMed  Google Scholar 

  101. Tanzi E, Esposito S, Bojanin J, Amendola A, Trabattoni D, Pariani E, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol. 2006;78:440–5.

    Article  PubMed  Google Scholar 

  102. Moss WJ, Clements CJ, Halsey NA. Immunization of children, at risk of infection with human immunodeficiency virus. Bull World Health Organ. 2003;81:61–70.

    PubMed  Google Scholar 

  103. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18:1443–51.

    Article  Google Scholar 

  104. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723–35.

    Google Scholar 

  105. Van Dyke RB, Wang L, Williams PL, Pediatric AIDS Clinical Trials Group 219C Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008;198:1599–608.

    Article  PubMed  Google Scholar 

  106. Vigano A, Giacomet V, Pattarino G, Fasan S, Zuccotti G, Brambilla P. Metabolic complications of HIV infection and its therapy in children. Futur HIV Therapy. 2007;1:181–90.

    Article  CAS  Google Scholar 

  107. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab. 2005;90:4075–80.

    Article  Google Scholar 

  108. Viganò A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, et al. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz. Antivir Ther. 2007;12:297–302.

    PubMed  Google Scholar 

  109. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr. 2001;27:30–4.

    CAS  PubMed  Google Scholar 

  110. Viganò A, Aldrovandi GM, Giacomet V, Merlo M, Martelli L, Beretta S, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther. 2005;10:917–24.

    PubMed  Google Scholar 

  111. Charakida M, Tousoulis D, Skoumas I, Pitsavos C, Vasiliadou C, Stefanadi E, et al. Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia. Atherosclerosis. 2009;204:532–7.

    Article  CAS  PubMed  Google Scholar 

  112. Viganò A, Cerini C, Meroni L, Giacomet V, Fabiano V et al. Long term HIV infection is associated with increased carotid intima media thickness in HIV infected adolescents. 16th Conference on Retroviruses and Opportunistic Infections, Montreal 2009, Abstract 915.

  113. Lester P, Chesney M, Cooke M, Weiss R, Whalley P, Perez B, et al. When the time comes to talk about HIV: factors associated with diagnostic disclosure and emotional distress in HIV-infected children. J Acquir Immune Defic Syndr. 2002;3:309–17.

    Google Scholar 

  114. Instone SL. Perceptions of children with HIV infection when not told for so long: implications for diagnosis disclosure. J Pediatr Health Care. 2000;14:235–43.

    CAS  PubMed  Google Scholar 

  115. Bachanas PJ, Kullgren KA, Schwartz KS, Lanier B, McDaniel JS, Smith J, et al. Predictors of psychological adjustment in school-age children infected with HIV. J Pediatr Psychol. 2001;26:343–52.

    Article  CAS  PubMed  Google Scholar 

  116. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. Psychiatric disorders in youth with perinatally acquired human immunodeficiency virus infection. Pediatr Infect Dis J. 2006;25:432–7.

    Article  PubMed  Google Scholar 

  117. Belzer ME, Fuchs DN, Luftman GS, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health. 1999;25:316–9.

    Article  CAS  PubMed  Google Scholar 

  118. Giacomet V, Albano F, Starace F, de Franciscis A, Giaquinto C, Gattinara GC, et al. Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study. Acta Paediatr. 2003;92:1398–402.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The organization of the meeting was supported by an unrestricted grant from Abbott S.p.A. Italy, held under the auspices of the Italian Society for Infectious and Tropical Diseases (Società Italiana di Malattie Infettive e Tropicali, SIMIT) and the Interdisciplinary Society for the Study of Sexually Transmitted Diseases (Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili, SIMaST).

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia, P.le Spedali Civili, 1, 25123, Brescia, Italy

    P. Nasta & G. Carosi

  2. Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani” IRCCS, Rome, Italy

    A. Ammassari & A. Antinori

  3. Clinica Pediatrica, Università degli Studi di Brescia, Brescia, Italy

    R. Badolato

  4. ImmunoInfettivologia, U.O. AIDS, Ospedale Pediatrico “Bambino Gesù”, Rome, Italy

    S. Bernardi, A. Martino & P. Rossi

  5. Dipartimento di Pediatria, Ospedale Pediatrico “Bambino Gesù”, Rome, Italy

    G. Castelli Gattinara

  6. Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera S. Paolo, Milan, Italy

    A. d’Arminio Monforte

  7. Clinica Pediatrica I, Dipartimento di Pediatria, Università degli Studi di Firenze, Florence, Italy

    M. De Martino & L. Galli

  8. Dipartimento di Oncologia, Università degli Studi di Padova, Padova, Italy

    A. De Rossi

  9. UO Malattie Infettive, Azienda Ospedaliera Cannizzaro, Catania, Italy

    P. Di Gregorio

  10. Department of Maternal and Pediatric Sciences, Università degli Studi di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy

    S. Esposito & N. Principi

  11. Medicina Specialistica AO, Universitaria Ferrarotto S. Bambino, Catania, Italy

    F. Fatuzzo

  12. Clinica Ostetrica, Ospedale Luigi Sacco, Milan, Italy

    S. Fiore

  13. Divisione Malattie Infettive, A.O. Umberto I, Siracusa, Italy

    A. Franco

  14. Dipartimento di Pediatria, A.O. OIRM-Sant’Anna, Turin, Italy

    C. Gabiano

  15. Clinica Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy

    O. Genovese

  16. Clinica Pediatrica, Università degli Studi di Milano, Ospedale Luigi Sacco, Milan, Italy

    V. Giacomet, S. Trotta, A. Viganò & G. Zuccotti

  17. Dipartimento di Pediatria, Università degli Studi di Napoli Federico II, Naples, Italy

    A. Giannattasio & A. Guarino

  18. Dipartimento di Pediatria, Università degli Studi di Padova, Padova, Italy

    C. Giaquinto, M. Penazzato & O. Rampon

  19. Servizio di Neonatologia, Ospedale San Martino, Genoa, Italy

    C. Gotta

  20. U.O.C. Malattie Infettive, Azienda Sanitaria Firenze, Florence, Italy

    F. Mazzotta

  21. Unità di Farmacocinetica Clinica, Fondazione IRCCS-Policlinico S, Matteo, Pavia, Italy

    M. B. Regazzi

  22. Clinica Malattie Infettive, Università degli Studi di Genova, Genoa, Italy

    R. Rosso

  23. Clinica Malattie Infettive, Università di Catania, Catania, Italy

    R. Russo

  24. U.O.C. Malattie Infettive, Az.Rilievo Naz. ed Alta Specializzazione “Civico, G. Di Cristina, M.Ascoli”, Palermo, Italy

    M. Saitta

  25. Clinica Pediatrica, Azienda Ospedaliera S. Paolo, Milan, Italy

    F. Salvini

Authors
  1. C. Giaquinto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Penazzato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Rosso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Bernardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. Rampon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Nasta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Ammassari
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Antinori
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. Badolato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Castelli Gattinara
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. d’Arminio Monforte
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. De Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A. De Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P. Di Gregorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. S. Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. F. Fatuzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. S. Fiore
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. A. Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. C. Gabiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. L. Galli
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. O. Genovese
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. V. Giacomet
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. A. Giannattasio
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. C. Gotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. A. Guarino
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. A. Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. F. Mazzotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. N. Principi
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. M. B. Regazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. P. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. R. Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. M. Saitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. F. Salvini
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. S. Trotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. A. Viganò
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. G. Zuccotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  37. G. Carosi
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The Italian Paediatric HIV Infection Working Group

Corresponding author

Correspondence to G. Carosi.

Additional information

The members of the Italian Paediatric HIV Infection Working Group are given in the Appendix.

Appendix

Appendix

The following doctors are members of the Italian Paediatric HIV Infection Guidelines Working Group: Aliffi A, Baldassari S, Bisicchia F, Bojanin J, Catuogno A, Cellini M, Chiappini E, Citton R, Dalle Nogare E R, Dedoni M, Di Bari C, Dodi I, Lipreri R, Mariani B, Mazza A, Palma P, Pivetti V, Pontrelli G, Tarallo L, Tel F, Tirantello M.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giaquinto, C., Penazzato, M., Rosso, R. et al. Italian consensus statement on paediatric HIV infection. Infection 38, 301–319 (2010). https://doi.org/10.1007/s15010-010-0020-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-010-0020-5

Keywords

Search

Navigation